Skip to main content
Top

06-09-2024 | Pancreatic Cancer | Original Paper

Leucine drives LAT1-related SNAIL upregulation in glucose-starved pancreatic cancer cells

Authors: Hajime Masubuchi, Yasuko Imamura, Takumi Kawaguchi, Hironori Koga

Published in: Medical Molecular Morphology

Login to get access

Abstract

Pancreatic cancer, a highly fibrotic and hypovascular tumor, is thought to have unique metabolic characteristics in surviving and proliferating in malnutritional microenvironments. In this study, we compared the differences in the ability of pancreatic cancer cells to adapt to glucose-free conditions with liver cancer cells, which are representative of hypervascular tumors. Three pancreatic cancer cells and two liver cancer cells were used to examine the transcriptional expression levels of molecules involved in intracellular amino acid uptake, epithelial–mesenchymal transition (EMT), and cancer stemness under glucose deprivation. The results showed that the proliferative activity of pancreatic cancer cells under glucose deprivation was significantly lower than that of liver cancer cells, but the expression levels of amino acid transporters were significantly higher. Among them, L-type amino acid transporter 1 (LAT1) upregulation was unique in concert with increased expression of the EMT regulator SNAIL and the cancer stemness marker doublecortin-like kinase 1. LAT1 knockdown canceled the upregulation of SNAIL in glucose-starved pancreatic cancer cells, suggesting a mechanistic link between the two molecules. When LAT1 was stimulated by its substrate leucine, the SNAIL expression was upregulated dose-dependently. Collectively, pancreatic cancer cells reprogrammed metabolism to adapt to energy crises involving leucine-induced SNAIL upregulation.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Yuen A, Díaz B (2014) The impact of hypoxia in pancreatic cancer invasion and metastasis. Hypoxia (Auckl) 2:91–106PubMed Yuen A, Díaz B (2014) The impact of hypoxia in pancreatic cancer invasion and metastasis. Hypoxia (Auckl) 2:91–106PubMed
3.
go back to reference Simeonov KP, Byrns CN, Clark ML, Norgard RJ, Martin B, Stanger BZ, Shendure J, McKenna A, Lengner CJ (2021) Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell 39:1150-1162.e9CrossRefPubMedPubMedCentral Simeonov KP, Byrns CN, Clark ML, Norgard RJ, Martin B, Stanger BZ, Shendure J, McKenna A, Lengner CJ (2021) Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell 39:1150-1162.e9CrossRefPubMedPubMedCentral
4.
go back to reference Yusuf S, Aretz P, Nickel AC, Westhoff P, Sharma A, Qin N, Remke M, Steiger HJ, Hänggi D, Liu H, Liu H, Neumann S, Reifenberger G, Maciaczyk J (2022) WNT/β-catenin-mediated resistance to glucose deprivation in glioblastoma stem-like cells. Cancers (Basel) 14:3165CrossRefPubMed Yusuf S, Aretz P, Nickel AC, Westhoff P, Sharma A, Qin N, Remke M, Steiger HJ, Hänggi D, Liu H, Liu H, Neumann S, Reifenberger G, Maciaczyk J (2022) WNT/β-catenin-mediated resistance to glucose deprivation in glioblastoma stem-like cells. Cancers (Basel) 14:3165CrossRefPubMed
5.
go back to reference Kodama M, Oshikawa K, Shimizu H, Yoshioka S, Takahashi M, Izumi Y, Bamba T, Tateishi C, Tomonaga T, Matsumoto M, Nakayama KI (2020) A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer. Nat Commun 11:1320CrossRefPubMedPubMedCentral Kodama M, Oshikawa K, Shimizu H, Yoshioka S, Takahashi M, Izumi Y, Bamba T, Tateishi C, Tomonaga T, Matsumoto M, Nakayama KI (2020) A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer. Nat Commun 11:1320CrossRefPubMedPubMedCentral
6.
go back to reference Sakaue T, Koga H, Iwamoto H, Nakamura T, Ikezono Y, Abe M, Wada F, Masuda A, Tanaka T, Fukahori M, Ushijima T, Mihara Y, Naitou Y, Okabe Y, Kakuma T, Ohta K, Nakamura KI, Torimura T (2019) Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer. Med Mol Morphol 52:198–208CrossRefPubMed Sakaue T, Koga H, Iwamoto H, Nakamura T, Ikezono Y, Abe M, Wada F, Masuda A, Tanaka T, Fukahori M, Ushijima T, Mihara Y, Naitou Y, Okabe Y, Kakuma T, Ohta K, Nakamura KI, Torimura T (2019) Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer. Med Mol Morphol 52:198–208CrossRefPubMed
7.
go back to reference Koga H, Harada M, Ohtsubo M, Shishido S, Kumemura H, Hanada S, Taniguchi E, Yamashita K, Kumashiro R, Ueno T, Sata M (2003) Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. Hepatology 37:1086–1096CrossRefPubMed Koga H, Harada M, Ohtsubo M, Shishido S, Kumemura H, Hanada S, Taniguchi E, Yamashita K, Kumashiro R, Ueno T, Sata M (2003) Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. Hepatology 37:1086–1096CrossRefPubMed
8.
go back to reference Tanaka T, Koga H, Suzuki H, Iwamoto H, Sakaue T, Masuda A, Nakamura T, Akiba J, Yano H, Torimura T, Kawaguchi T (2024) Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells. Hepatol Int 18:984–997CrossRefPubMed Tanaka T, Koga H, Suzuki H, Iwamoto H, Sakaue T, Masuda A, Nakamura T, Akiba J, Yano H, Torimura T, Kawaguchi T (2024) Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells. Hepatol Int 18:984–997CrossRefPubMed
9.
go back to reference Xu D, Hemler ME (2005) Metabolic activation-related CD147-CD98 complex. Mol Cell Proteom 4:1061–1071CrossRef Xu D, Hemler ME (2005) Metabolic activation-related CD147-CD98 complex. Mol Cell Proteom 4:1061–1071CrossRef
10.
go back to reference Ikezono Y, Koga H, Akiba J, Abe M, Yoshida T, Wada F, Nakamura T, Iwamoto H, Masuda A, Sakaue T, Yano H, Tsuruta O, Torimura T (2017) Pancreatic neuroendocrine tumors and EMT behavior are driven by the CSC marker DCLK1. Mol Cancer Res 15:744–752CrossRefPubMed Ikezono Y, Koga H, Akiba J, Abe M, Yoshida T, Wada F, Nakamura T, Iwamoto H, Masuda A, Sakaue T, Yano H, Tsuruta O, Torimura T (2017) Pancreatic neuroendocrine tumors and EMT behavior are driven by the CSC marker DCLK1. Mol Cancer Res 15:744–752CrossRefPubMed
11.
go back to reference Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, Akita H, Takiuchi D, Hatano H, Nagano H, Barnard GF, Doki Y, Mori M (2010) CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 120:3326–3339CrossRefPubMedPubMedCentral Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, Akita H, Takiuchi D, Hatano H, Nagano H, Barnard GF, Doki Y, Mori M (2010) CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 120:3326–3339CrossRefPubMedPubMedCentral
12.
go back to reference Nusse R, Clevers H (2017) Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell 169:985–999CrossRefPubMed Nusse R, Clevers H (2017) Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell 169:985–999CrossRefPubMed
13.
go back to reference Kanai Y (2022) Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. Pharmacol Ther 230:107964CrossRefPubMed Kanai Y (2022) Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. Pharmacol Ther 230:107964CrossRefPubMed
14.
go back to reference Hayashi K, Anzai N (2022) L-type amino acid transporter 1 as a target for inflammatory disease and cancer immunotherapy. J Pharmacol Sci 148:31–40CrossRefPubMed Hayashi K, Anzai N (2022) L-type amino acid transporter 1 as a target for inflammatory disease and cancer immunotherapy. J Pharmacol Sci 148:31–40CrossRefPubMed
15.
go back to reference Nishikubo K, Ohgaki R, Liu X, Okanishi H, Xu M, Endou H, Kanai Y (2023) Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells. Cancer Cell Int 23:116CrossRefPubMedPubMedCentral Nishikubo K, Ohgaki R, Liu X, Okanishi H, Xu M, Endou H, Kanai Y (2023) Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells. Cancer Cell Int 23:116CrossRefPubMedPubMedCentral
16.
go back to reference Rossi M, Turati F, Strikoudi P, Ferraroni M, Parpinel M, Serraino D, Negri E, La Vecchia C (2022) Dietary intake of branched-chain amino acids and pancreatic cancer risk in a case-control study from Italy. Br J Nutr 23:1–19 Rossi M, Turati F, Strikoudi P, Ferraroni M, Parpinel M, Serraino D, Negri E, La Vecchia C (2022) Dietary intake of branched-chain amino acids and pancreatic cancer risk in a case-control study from Italy. Br J Nutr 23:1–19
17.
go back to reference Li JT, Yin M, Wang D, Wang J, Lei MZ, Zhang Y, Liu Y, Zhang L, Zou SW, Hu LP, Zhang ZG, Wang YP, Wen WY, Lu HJ, Chen ZJ, Su D, Lei QY (2020) BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma. Nat Cell Biol 22:167–174CrossRefPubMed Li JT, Yin M, Wang D, Wang J, Lei MZ, Zhang Y, Liu Y, Zhang L, Zou SW, Hu LP, Zhang ZG, Wang YP, Wen WY, Lu HJ, Chen ZJ, Su D, Lei QY (2020) BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma. Nat Cell Biol 22:167–174CrossRefPubMed
18.
go back to reference Liu KA, Lashinger LM, Rasmussen AJ, Hursting SD (2014) Leucine supplementation differentially enhances pancreatic cancer growth in lean and overweight mice. Cancer Metab 2:6CrossRefPubMedPubMedCentral Liu KA, Lashinger LM, Rasmussen AJ, Hursting SD (2014) Leucine supplementation differentially enhances pancreatic cancer growth in lean and overweight mice. Cancer Metab 2:6CrossRefPubMedPubMedCentral
19.
go back to reference Rii J, Sakamoto S, Mizokami A, Xu M, Fujimoto A, Saito S, Koike H, Tamura T, Arai T, Yamada Y, Goto Y, Sazuka T, Imamura Y, Suzuki K, Kanai Y, Anzai N, Ichikawa T (2024) L-type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel-resistant prostate cancer by inhibiting cyclin-dependent kinase activity. Cancer Sci 115:937–953CrossRefPubMedPubMedCentral Rii J, Sakamoto S, Mizokami A, Xu M, Fujimoto A, Saito S, Koike H, Tamura T, Arai T, Yamada Y, Goto Y, Sazuka T, Imamura Y, Suzuki K, Kanai Y, Anzai N, Ichikawa T (2024) L-type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel-resistant prostate cancer by inhibiting cyclin-dependent kinase activity. Cancer Sci 115:937–953CrossRefPubMedPubMedCentral
Metadata
Title
Leucine drives LAT1-related SNAIL upregulation in glucose-starved pancreatic cancer cells
Authors
Hajime Masubuchi
Yasuko Imamura
Takumi Kawaguchi
Hironori Koga
Publication date
06-09-2024
Publisher
Springer Nature Singapore
Published in
Medical Molecular Morphology
Print ISSN: 1860-1480
Electronic ISSN: 1860-1499
DOI
https://doi.org/10.1007/s00795-024-00404-0